Jishi Tongguang Pharmaceutical Technology

Jishi Tongguang Pharmaceutical Technology (trading as TongEYE) is a Chinese biotechnology company founded in October 2023 and headquartered in Ningbo, Zhejiang. The company specializes in the development of innovative cell-based and protein-based therapeutics for complex and refractory ophthalmic diseases, with a primary focus on stem cell regenerative therapies. Its core pipeline asset, TE02102, is an induced pluripotent stem cell (iPSC)-derived youthful retinal pigment epithelium (RPE) cell injection currently in the Investigator-Initiated Trial (IIT) stage for the treatment of dry age-related macular degeneration (dry AMD). TongEYE's broader pipeline also includes iPSC-derived corneal endothelial cell (CEC) transplantation for bullous keratitis, iPSC-derived retinal progenitor cell (RPC) transplantation for retinitis pigmentosa, and TE01311, a protein-based therapeutic for diabetic eye disease. The company leverages its proprietary iPSC differentiation platform to significantly reduce differentiation times and manufacturing costs, aiming to provide accessible regenerative treatments for blinding eye diseases globally.